SpaceX Delays Starship V3 Launch Ahead of Potential Record IPO 
Huawei Chip Breakthrough Sparks Rally in Hong Kong AI and Semiconductor Stocks 
Samsung to Invest $1.5 Billion in Vietnam Semiconductor Testing Plant by 2027 
SK Hynix Joins $1 Trillion Club as AI Chip Demand Fuels Stock Surge 
Oil Prices Jump as U.S. Strikes in Iran Raise Fears Over Strait of Hormuz Supply Disruptions 
BOJ Signals Possible Rate Hike as Middle East Tensions Fuel Inflation Concerns 
Uruguay Central Bank Holds Interest Rate at 5.75% Amid Inflation and Oil Price Concerns 
Samsung Shares Surge After Strike Deal Eases Labor Tensions 
Nikkei Hits Record High as AI Chip Stocks Power Japan Market Rally 
BOJ Governor Ueda Warns Oil Price Shock Could Trigger Persistent Inflation 
CTOC Goes Live on Bitget Wallet Trading, Expanding Global Access to AI-Powered Healthcare Data Ecosystem 
Dollar Weakens as Iran Peace Hopes Lift EUR/USD and Risk Sentiment 
Macquarie Names Five Taiwan AI Stocks Set to Benefit From Data Center Growth in 2026 
European EV Sales Surge in April 2026 as Tesla and Chinese Automakers Gain Ground 
Puerto Rico Economic Development Chief Resigns Amid Government Shake-Up 
European Stocks Rise as AI Optimism Offsets U.S.-Iran Tensions 
ASX Shares Plunge as Rising Tech Upgrade Costs Shake Investor Confidence 
Lotte Biologics has inked a memorandum of understanding (MOU) with Roche Diagnostics to bolster its Contract Development and Manufacturing Organization (CDMO) capabilities. This collaboration signifies major diagnostics, hardware, and automation advancements for Lotte's upcoming Korean production plants.
On Wednesday, Aug. 9, Lotte Biologics said it will work with Roche Diagnostics to improve the productivity and quality of its productions. The company said they would also team up to establish hardware and automation systems for Lotte's upcoming production plants in Korea, as per Korea Joongang Daily.
The MOU was signed at Roche Diagnostics CustomBiotech Center in Penzberg, Germany. Lotte Biologics' chief executive officer, Richard Lee; Roche Diagnostics CustomBiotech's vice president, Rainer Mueller; and Roche Diagnostics Korea's general manager, Kit Tang, were all present at the signing ceremony.
With the deal in place, Lotte Biologics aims to amplify its credibility with future global clients. The agreement will also serve as the forefront to underpin and shore up Roche Diagnostics' supply network in the Asian market. This will also give better treatment access to patients around the world.
"Through this MOU, we plan to enhance the production process capabilities of our Korean Mega Plant in collaboration with Roche Diagnostics," Lotte Biologics chief Richard Lee said in a press release. "Through synergy with Roche Diagnostics, an industry leader in the in vitro diagnostic field, LOTTE hopes to improve the efficiency of its operations at the forthcoming Korean Mega Plant, simultaneously augmenting the quality of our manufacturing and fulfilling customer needs."
Finally, Business Korea reported that Lotte Biologics and Roche Diagnostics will cooperate on various business fronts, including installing automation systems at the former's Mega Plants that will be built in Korea. The latter will also provide technical consulting and equipment support for the facilities.
Photo by: Lotte Biologics Newsroom
